文献速递类风湿关节炎

类风湿关节炎风险关节痛患者HAQ-DI最小临床重要差异评估

Assessment of the minimal clinically important difference for the Health Assessment Questionnaire Disability Index in patients with arthralgia at risk for progression to rheumatoid arthritis.
PubMed 文献 · RMD Open · 2025-09-21

研究旨在确定类风湿关节炎(RA)风险期关节痛患者健康评估问卷残疾指数(HAQ-DI)的最小临床重要差异(MCID)。基于TREAT EARLIER试验中97例接受甲氨蝶呤治疗且有基线和12个月HAQ-DI数据的患者,以SF-36锚定问题确定MCID。结果显示改善的MCID为-0.07±0.28,恶化的MCID为+0.05±0.6,低于RA中通常报告的范围(-0.06至-0.38)。

要点

  • RA风险期关节痛患者HAQ-DI改善的MCID为-0.07±0.28。
  • 该MCID低于RA中通常报告的MCID范围(-0.06至-0.38)。
  • 在关节痛阶段,相比RA,HAQ-DI较小的改善即具有临床相关性。

核心结论

  • 在RA风险期关节痛患者中,HAQ-DI改善的MCID为-0.07,低于RA中通常报告的值,意味着关节痛阶段较小的HAQ-DI改善即具有临床相关性。

研究设计与样本

  • 研究纳入TREAT EARLIER试验中97例接受甲氨蝶呤治疗且有基线和12个月HAQ-DI数据的关节痛患者,使用SF-36锚定问题确定MCID。
  • 同时通过文献研究确定RA中基线HAQ-DI与MCID估计值的相关性。

主要发现

  • 在RA中,MCID估计值范围为-0.06至-0.38,较高的绝对HAQ值与较高的MCID相关。
  • 在研究的风险期患者中,改善的MCID为-0.07±0.28。
  • 恶化的MCID为+0.05±0.6。

关键数值与推荐

  • 改善的MCID定义为报告「稍好」和「稍差」患者HAQ-DI评分平均变化。
  • RA中MCID估计值范围为-0.06至-0.38。
  • 风险期关节痛患者改善的MCID为-0.07±0.28,恶化的MCID为+0.05±0.6。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Patients with arthralgia at-risk for rheumatoid arthritis (RA) experience considerable functional disability, though generally less than at RA diagnosis. Secondary prevention trials have shown that treatment can improve disability in patients with arthralgia. However, interpreting the clinical relevancy of the improvements in Health Assessment Questionnaire Disability Index (HAQ-DI) is hampered by the lack of a defined minimal clinically important difference (MCID) in this disease stage. Results from other disciplines than rheumatology suggested that the MCID depends on absolute severity values. Therefore, we hypothesised that the MCID for HAQ-DI in RA depends on absolute values. We aimed to investigate this and, if so, to determine the MCID for disability in the risk setting. METHODS: We studied the literature and determined the correlation of baseline HAQ-DI and MCID estimates in RA. To determine the MCID in arthralgia, we studied 97 patients treated with methotrexate in the TREAT EARLIER trial with HAQ-DI data at baseline and 12 months. At 12 months, a short-form 36 questionnaire anchor question compared patients' general health to that of 1 year before. The MCID was determined using the mean change in HAQ-DI score of patients reporting 'somewhat better' and 'somewhat worse'. RESULTS: In RA, the MCID estimates ranged from -0.06 to -0.38, and higher absolute HAQ values correlated with a higher MCID. In the at-risk patients studied, the MCID for improvement was -0.07±0.28. Likewise, for deterioration, the MCID was +0.05±0.6. CONCLUSION: In arthralgia at-risk for RA, the MCID for improvement in HAQ-DI is -0.07. This is lower than generally reported in RA. This implies that in arthralgia, compared with RA, smaller improvements in HAQ-DI are clinically relevant.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Claassen S, van Steenbergen HW, van der Helm-van Mil AHM, et al. Assessment of the minimal clinically important difference for the Health Assessment Questionnaire Disability Index in patients with arthralgia at risk for progression to rheumatoid arthritis. RMD Open. 2025. PMID: 40983396. doi:10.1136/rmdopen-2025-005899

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。